Disease Fact Sheet: Amyotrophic Lateral Sclerosis (ALS)
Clinical Status: There are no clinical trials aimed at replacing the motor neurons lost in ALS. However, there are completed and ongoing trials using stem cells to modulate disease progression in ALS. These trials have generally used bone marrow-derived mesenchymal stem cells (MSCs), which are typically expanded in culture and then transplanted into the cerebral spinal fluid (CSF). Other approaches, such as injections of human fetal spinal cord-derived neural stem cells and genetically engineered neural progenitor cells releasing GDNF, have also reached clinical trials. Additionally, there has been a small Phase 1 trial using autologous Tregs. Download the ALS Fact Sheet to learn more information about these trials and find additional resources.